Search alternatives:
significantly improved » significantly increased (Expand Search)
improved decrease » improved urease (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
small decrease » small increased (Expand Search)
significantly improved » significantly increased (Expand Search)
improved decrease » improved urease (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
small decrease » small increased (Expand Search)
-
101
-
102
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
103
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
104
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
105
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
106
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
107
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
108
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
109
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
110
Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides
Published 2024“…Among them, W<sub>3</sub>BipY<sub>8</sub>-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W<sub>3</sub>BipY<sub>8</sub> but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W<sub>3</sub>BipY<sub>8</sub>. …”
-
111
Significant associations in GWAS.
Published 2025“…<div><p>Decreased nitric oxide (NO) production from the vascular endothelium is a major factor for vascular aging. …”
-
112
-
113
C2f-E improvement process.
Published 2025“…<div><p>In the domain of remote sensing image small target detection, challenges such as difficulties in extracting features of small targets, complex backgrounds that easily lead to confusion with targets, and high computational complexity with significant resource consumption are prevalent. …”
-
114
-
115
BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma.
Published 2024Subjects: -
116
-
117
-
118
-
119
-
120